StockData
Rigel Pharmaceuticals Inc logo

Rigel Pharmaceuticals Inc (RIGL) stock

RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/30
$42.92−0.81 (-1.85%)

Close on Nov 17, 2026Market cap $801.74MP/E 2.7Yield –

Rigel Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Rigel Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was $87.05M, down 16.8% year over year. For fiscal 2025 it was $125.47M, up 418.6% from the year before. The highest annual figure on record is $125.47M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$125.47M+418.6%
FY2024Dec 31, 2024$24.19M–
FY2023Dec 31, 2023-$20.49M–
FY2022Dec 31, 2022-$55.55M–
FY2021Dec 31, 2021-$12.50M–
FY2020Dec 31, 2020-$28.97M–
FY2019Dec 31, 2019-$69.09M–
FY2018Dec 31, 2018-$72.68M–
FY2017Dec 31, 2017-$79.62M–
FY2016Dec 31, 2016-$69.74M–
FY2015Dec 31, 2015-$51.74M–
FY2014Dec 31, 2014-$91.25M–
FY2013Dec 31, 2013-$89.47M–
FY2012Dec 31, 2012-$99.38M–
FY2011Dec 31, 2011-$86.37M-344.6%
FY2010Dec 31, 2010$35.32M–
FY2009Dec 31, 2009-$112.04M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$23.58M-61.4%
Q1 FY2026Mar 31, 2026$11.89M-7.0%
Q4 FY2025Dec 31, 2025$23.17M+39.1%
Q3 FY2025Sep 30, 2025$28.42M+102.2%
Q2 FY2025Jun 30, 2025$61.10M+13569.6%
Q1 FY2025Mar 31, 2025$12.77M–
Q4 FY2024Dec 31, 2024$16.66M+747.2%
Q3 FY2024Sep 30, 2024$14.06M–
Q2 FY2024Jun 30, 2024$447.00K–
Q1 FY2024Mar 31, 2024-$6.97M–
Q4 FY2023Dec 31, 2023$1.97M-5.4%
Q3 FY2023Sep 30, 2023-$4.47M–
Q2 FY2023Jun 30, 2023-$5.27M–
Q1 FY2023Mar 31, 2023-$12.73M–
Q4 FY2022Dec 31, 2022$2.08M–
Q3 FY2022Sep 30, 2022-$18.40M–
Q2 FY2022Jun 30, 2022-$12.97M–
Q1 FY2022Mar 31, 2022-$26.26M-162.9%
Q4 FY2021Dec 31, 2021-$21.42M–
Q3 FY2021Sep 30, 2021-$19.79M–
Q2 FY2021Jun 30, 2021-$13.05M–
Q1 FY2021Mar 31, 2021$41.76M+98.6%
Q4 FY2020Dec 31, 2020-$18.83M–
Q3 FY2020Sep 30, 2020-$13.78M–
Q2 FY2020Jun 30, 2020-$17.39M–
Q1 FY2020Mar 31, 2020$21.03M–
Q4 FY2019Dec 31, 2019-$17.34M-784.7%
Q3 FY2019Sep 30, 2019-$12.04M–
Q2 FY2019Jun 30, 2019-$21.34M–
Q1 FY2019Mar 31, 2019-$18.38M–
Q4 FY2018Dec 31, 2018$2.53M–
Q3 FY2018Sep 30, 2018-$24.37M–
Q2 FY2018Jun 30, 2018-$26.11M–
Q1 FY2018Mar 31, 2018-$24.73M–
Q4 FY2017Dec 31, 2017-$26.22M–
Q3 FY2017Sep 30, 2017-$17.86M–
Q2 FY2017Jun 30, 2017-$19.34M–
Q1 FY2017Mar 31, 2017-$16.20M–
Q4 FY2016Dec 31, 2016-$15.79M–
Q3 FY2016Sep 30, 2016-$22.74M–

More Rigel Pharmaceuticals figures

See a number that looks wrong?